Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age \>/= 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2~* Patients for whom no standard curable therapy exists~* Life expectancy of \>/= 12 weeks~* Last dose of systemic anti-neoplastic therapy \> 21 days prior to first RO6927005 infusion~* Palliative radiotherapy is allowed up to 2 weeks before the first RO6927005 infusion; palliative 8 Gy radiotherapy is allowed during therapy.~* All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure must have resolved to Grade \</= 1, except alopecia (any grade) and Grade 2 peripheral neuropathy~* Adequate hematological, liver, and renal function~* Negative serum or urine pregnancy test within 7 days prior to study treatment in premenopausal women and women \</= 2 years after menopause (menopause is defined as amenorrhea for \>/= 2 years)~* Agreement to use adequate contraceptive methods per protocol~* Measurable and/or evaluable disease as per the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1) \[Groups 1, 2 of Part A and Group 3 of Part B\]~Inclusion Criteria Part A: MAD~* Metastatic and/or locally advanced malignant solid tumors enriched in tumor types known to be mesothelin expressing~* Archival sample or fresh biopsy or tumor effusion must be available for retrospective mesothelin analysis~Inclusion Criteria Part A: MAD and Extension Phase (Group 1 and Group 2)~* Histologically confirmed metastatic and/or advanced malignant mesothelin-positive solid tumors as determined by central pathology lab review~* Patients must be willing to provide a screening and post-dose biopsy for biomarker analysis (extension phase only)~* Mesothelin-positive refractory/recurrent solid tumors, other than malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDA) (Group 1 only)~* Mesothelin-positive refractory/recurrent MPM (Group 2 only)~Inclusion Criteria Part B~* Histologically confirmed metastatic and/or advanced mesothelin-positive PDA as determined by central pathology lab review~* In the extension phase, patients must be willing to provide a screening and post-dose biopsy for biomarker analysis~Exclusion Criteria:~* Known or clinically suspected central nervous system (CNS) primary tumors or metastases including leptomeningeal metastases; history or clinical evidence of CNS metastases unless they have been previously treated, are asymptomatic, and have had no requirement for steroids or enzyme-inducing anticonvulsants in the last 14 days~* Evidence of significant, uncontrolled concomitant diseases which could affect compliance with the protocol or interpretation of results, including significant pulmonary disease other than primary cancer, uncontrolled diabetes mellitus, and/or significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, unstable angina, or clinically significant pericardial effusion)~* Active or uncontrolled infections~* Known HIV or known active HBV or HCV infection~* Patients with extrapleural pneumonectomy (EPP)~* Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug~* Major surgery or significant traumatic injury \< 28 days prior to the first RO6927005 infusion (excluding biopsies) or anticipation of the need for major surgery during study treatment~* Dementia or altered mental status that would prohibit informed consent~* Live attenuated vaccinations 14 days prior to treatment~* Pregnant or breast-feeding women~* Known hypersensitivity to any of the components of RO6927005~* High doses of systemic corticosteroids within 7 days prior to first dosing. High dose is considered as \> 20 mg of dexamethasone a day (or equivalent) for \> 7 consecutive days~Exclusion Criteria (Part B):~* Patients with contra-indication and/or history of severe hypersensitivity reactions to gemcitabine and/or nab-paclitaxel as mentioned in the locally approved label

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A MAD Phase RO6927005 Monotherapy (Type: EXPERIMENTAL): RO6927005 given as a single agent in participants with tumors known to be mesothelin expressing and with mesothelin-positive tumors. MAD = multiple ascending dose.
- Part A Extension Phase Group 1 (Type: EXPERIMENTAL): RO6927005 given as a single agent in participants with mesothelin-positive refractory/recurrent solid tumors, other than malignant pleural mesothelioma (MPM) and pancreatic ductal adenocarcinoma (PDA)
- Part A Extension Phase Group 2 (Type: EXPERIMENTAL): RO6927005 given as a single agent in participants with mesothelin-positive metastatic and/or advanced PDA
- Part B MAD Phase (Type: EXPERIMENTAL): RO6927005 with gemcitabine/nab-paclitaxel in participants with mesothelin-positive metastatic and/or advanced PDA
- Part B Extension Phase (Type: EXPERIMENTAL): RO6927005 with gemcitabine/nab-paclitaxel in participants with PDA

Based on this trial design, predict the completion outcome and termination type (if applicable).